Imunon, Inc. Files S-1 for Public Offering
Ticker: IMNN · Form: S-1 · Filed: Aug 29, 2024 · CIK: 749647
Sentiment: neutral
Topics: s-1, registration-statement, public-offering
TL;DR
Imunon (formerly Celsion) is filing an S-1 to sell stock, get ready for a public offering.
AI Summary
Imunon, Inc. filed an S-1 registration statement on August 29, 2024, to register securities for public offering. The company, formerly known as Celsion Corp, is incorporated in Delaware and headquartered in Lawrenceville, NJ. This filing indicates a move towards raising capital through the sale of stock.
Why It Matters
This S-1 filing signals Imunon, Inc.'s intention to raise capital by selling its securities to the public, which could fund its business operations and growth initiatives.
Risk Assessment
Risk Level: medium — As an S-1 filing, it indicates a company is preparing to go public or raise significant capital, which inherently carries market and execution risks.
Key Numbers
- 333-281834 — SEC File Number (Identifies this specific registration statement with the SEC.)
Key Players & Entities
- Imunon, Inc. (company) — Registrant
- Celsion Corp (company) — Former company name
- August 29, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Lawrenceville, NJ (location) — Principal business address
- 333-281834 (registration_number) — SEC file number
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public.
What was Imunon, Inc. previously known as?
Imunon, Inc. was formerly known as Celsion Corp, with name changes also noted from CELSION CORP and CHEUNG LABORATORIES INC.
Where is Imunon, Inc. located?
Imunon, Inc.'s principal business address is 997 Lenox Drive, Suite 100, Lawrenceville, New Jersey 08648.
When was this S-1 filing submitted?
This S-1 filing was submitted to the SEC on August 29, 2024.
In which state is Imunon, Inc. incorporated?
Imunon, Inc. is incorporated in Delaware.
Filing Stats: 4,639 words · 19 min read · ~15 pages · Grade level 13.9 · Accepted 2024-08-29 09:58:39
Key Financial Figures
- $0.01 — o 5,000,000 shares of the common stock, $0.01 par value per share, of Imunon, Inc., o
- $1.15 — rted sale price of our common stock was $1.15 per share. Investing in our securitie
- $2.00 — rrants, which have an exercise price of $2.00 and will expire five and one half years
- $10.0 million — we would receive aggregate proceeds of $10.0 million. If we receive any cash proceeds, we cu
- $2.19 — ng a weighted average exercise price of $2.19 per share; 789,297 shares of common s
- $2.87 — eighted average grant day fair value of $2.87 per share; 160,060 shares of common s
- $18.86 — ng a weighted average exercise price of $18.86 per share; and 779,020 shares of comm
Filing Documents
- forms-1.htm (S-1) — 297KB
- ex5-1.htm (EX-5.1) — 14KB
- ex23-1.htm (EX-23.1) — 4KB
- ex107.htm (EX-FILING FEES) — 21KB
- ex5-1_001.jpg (GRAPHIC) — 40KB
- ex5-1_002.jpg (GRAPHIC) — 84KB
- 0001493152-24-034312.txt ( ) — 761KB
- imnn-20240630.xsd (EX-101.SCH) — 3KB
- imnn-20240630_def.xml (EX-101.DEF) — 30KB
- imnn-20240630_lab.xml (EX-101.LAB) — 36KB
- imnn-20240630_pre.xml (EX-101.PRE) — 27KB
- forms-1_htm.xml (XML) — 5KB
RISK FACTORS
RISK FACTORS 4 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 5
USE OF PROCEEDS
USE OF PROCEEDS 6 DIVIDEND POLICY 7 MARKET FOR OUR COMMON STOCK 8 SELLING STOCKHOLDERS 9 PLAN OF DISTRIBUTION 11 LEGAL MATTERS 12 EXPERTS 12 WHERE YOU CAN FIND MORE INFORMATION 12 INCORPORATION OF DOCUMENTS BY REFERENCE 12 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, under which the Selling Stockholders may, from time to time, sell the securities described in this prospectus in one or more offerings . This prospectus contains information that you should consider when making your investment decision. Neither we nor the Selling Stockholders have authorized anyone to provide you with information that is different from or in addition to the information contained in this prospectus. Accordingly, neither we nor any Selling Stockholder takes any responsibility for, or can provide any assurance as to the reliability of, any information that others may give. The Selling Stockholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than where offers and sales of these securities are permitted or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus is accurate only as of the date of this prospectus and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, or any sale of our common stock . Our business, financial condition, results of operations and prospects may have changed materially since those dates. Unless the context otherwise requires, "Imunon," "IMNN," "the Company," "we," "us